Bionano

Canaccord Genuity Acts as Exclusive Financial Advisor to Bionano Genomics Inc. on its Balance Sheet Recapitalization

Canaccord Genuity is pleased to announce that on May 28, 2024, Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ: BNGO) has entered into definitive agreement for a private placement convertible note financing for $20 million. The proceeds will allow the Company to completely retire the convertible debt financing the Company entered into in October 2023 that was subsequently amended in February 2024.

This new financing strengthens the Company’s capital structure and provides significant financial flexibility by retiring near-term debt maturities, deferring principal redemption payments, and further reducing near-term cash needs. Additionally, this new financing reinforces the strategic plan set out by the Company in February 2024, enhancing the Company’s ability to continue its review of strategic alternatives to maximize shareholder value.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

Canaccord Genuity acted as exclusive financial advisor and private placement agent to Bionano.